Skip to main content


Serial Biopsies Identify Treatment Resistance and Inform Therapy Decisions in Patients with Advanced Solid Malignancies
Cancers often arise as a result of genomic instability and the evolution of neoplastic cell populations with variable types of genetic alterations.
Read More ›

Low-Grade Gliomas as a Model Malignancy for Preventing Oncogenic Signaling Through BRAF Inhibition
Low-grade glioma (LGG) represents the most frequently occurring central nervous system tumor among children, accounting for nearly one-third of all pediatric brain tumors.
Read More ›

Recent Advances in Therapeutic Targeting of NRG1 Fusion-Bearing Cancers
Oncogenic gene fusions are hybrid genes caused by DNA rearrangements, leading to the generation of protein products that can perturb key components of cellular activity, thus resulting in deregulated growth, proliferation, and differentiation.
Read More ›

New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?

What the Next Generation of Cancer Biomarkers May Involve

How MSI and TMB Factor into Current Biomarker Testing Panels

Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

The Greatest Challenges in Incorporating Biomarkers into Cancer Care

The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

Page 1 of 3